The president’s proposed 25 percent tariffs on pharmaceutical imports will be catastrophic. There are other options to bring ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

As a sales rep for drug manufacturers Questcor, Lisa Pratta always suspected the company’s business practices weren’t just ...

Billions of dollars worth of U.S. biomanufacturing plant development has been announced, and site selection will likely be ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

Sun Pharmaceutical Industries Ltd has announced top-line results from the Phase-2 clinical trial evaluating the safety and ...

Research modelling the effect of U.S. prices for patented medicines if they are equal to or less than Canada’s shows prices ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

The American Society for Clinical Oncology’s Annual Meeting for 2025 is, if nothing else, absolutely overwhelming and ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...